INmune Bio (INMB) Expected to Release Earnings on Thursday

INmune Bio (NASDAQ:INMB) is expected to be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect INmune Bio to announce earnings of ($0.2067) per share and revenue of $1.1550 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04.

INmune Bio Trading Down 1.2%

INMB opened at $1.69 on Thursday. The company’s 50 day moving average is $1.56 and its 200-day moving average is $1.46. INmune Bio has a 1-year low of $1.09 and a 1-year high of $3.00. The company has a market cap of $44.92 million, a P/E ratio of -1.01 and a beta of 0.97.

Analyst Ratings Changes

INMB has been the subject of several research reports. Wall Street Zen downgraded shares of INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Weiss Ratings raised shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Institutional Trading of INmune Bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in INmune Bio in the 4th quarter valued at approximately $32,000. XTX Topco Ltd grew its holdings in INmune Bio by 41.3% during the 4th quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock worth $107,000 after acquiring an additional 20,121 shares during the last quarter. Quadrature Capital Ltd bought a new stake in INmune Bio during the 4th quarter worth approximately $26,000. Jain Global LLC acquired a new position in INmune Bio in the 4th quarter valued at approximately $66,000. Finally, Charles Schwab Investment Management Inc. increased its position in INmune Bio by 20.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after acquiring an additional 8,427 shares during the period. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.